Navigation Links
Synthetic Biology: The Next Biotech Revolution Is Brewing
Date:3/24/2009

Landmark report addresses regulatory oversight for emerging technology

WASHINGTON, March 24 /PRNewswire-USNewswire/ -- The safety of early applications of synthetic biology may be adequately addressed by the existing regulatory framework for biotechnology, especially in contained laboratories and manufacturing facilities. But further advances in this emerging field are likely to create significant challenges for U.S. government oversight, according to a new report authored by Michael Rodemeyer of the University of Virginia. Synthetic biology promises major advances in areas such as biofuels, specialty chemicals, and agriculture and drug products.

In New Life, Old Bottles: Regulating First-Generation Products of Synthetic Biology, Rodemeyer examines the benefits and drawbacks of using the existing U.S. regulatory framework for biotechnology to cover the new products and processes enabled by synthetic biology. According to Rodemeyer, initial synthetic biology products will be relatively simple modifications of current technology and can be addressed by existing biotechnology regulations with only modest revisions.

However, as the technology develops, regulatory agencies such as the Environmental Protection Agency and Food and Drug Administration will face challenges in assessing potential risks and the adequacy of controls, especially if complex synthetic microorganisms are released into the environment. Today's risk assessment practices and laws like the Toxic Substances Control Act and Federal Food, Drug, and Cosmetic Act, simply are not designed to handle 21st century technological advances.

"Before synthetic biology matures, Congress and policymakers should consider how to rationalize and modernize the regulation of new converging technologies, instead of attempting to shoehorn each new area of technological development into laws previously written for a different set of issues and potential risks," Rodemeyer argues.

A five-minute video interview with Rodemeyer is available at: http://www.synbioproject.org/news/project/rodemeyer/.

"It would be easy to relegate discussions about oversight to the backburner. But procrastination bears a risk. A productive dialogue may become more difficult as synthetic biology evolves and stakeholders become divided in their opinions about benefits and risks. The existing regulatory framework for biotechnology is the natural starting point for synthetic biology oversight. But the framework is at best a patchwork quilt of decades old guidelines and laws that could impede innovation, undercut public confidence, and compromise the promised benefits of synbio," says David Rejeski, the director of the Foresight & Governance Project at the Woodrow Wilson International Center for Scholars. "Policymakers, industry, and other key stakeholders should start a discussion now on the basic question of whether existing regulations will work with advanced synthetic biology, and if not, what changes may be needed to ensure safe development and application of the science."

For Rodemeyer's report and more information about synthetic biology, see: www.synbioproject.org.

ABOUT SYNTHETIC BIOLOGY

The Rathenau Instituut, a unit of the Royal Netherlands Academy of Arts and Sciences (KNAW), describes synbio as the convergence of molecular biology, information technology and nanotechnology, leading to the systematic design of biological systems.

The U.S. is considered the world leader in this emerging field of science. Lux Research, however, claims government funding is more coordinated in Europe, led by the European Union's 6th Framework program (FP6) which provides millions of euros in funding for synbio research. Corporations and venture capitalists are investing hundreds of millions of dollars into startups like Amyris, LS9 and Gevo. Some estimate that by 2015, a fifth of the chemical industry (worth $1.8 trillion) could be dependent on synthetic biology.

ABOUT THE AUTHOR

From 2000 until 2005, Mr. Rodemeyer was the Executive Director of the Pew Initiative on Food and Biotechnology, a nonprofit research and education project on genetically modified foods funded by a grant from The Pew Charitable Trusts. Before that, Rodemeyer held a variety of posts in the federal government, including Assistant Director for Environment in the Office of Science and Technology Policy in the Clinton administration, and Chief Democratic Counsel for the U.S. Congress House Committee on Science and Technology. From 1976 through 1984, he was an attorney with the Federal Trade Commission, working on consumer protection and antitrust issues.

Currently, Mr. Rodemeyer is an independent consultant on science, technology and environmental policy. He is also an adjunct instructor in the Science, Technology and Society Department in the School of Engineering and Applied Sciences at the University of Virginia.

His report was made possible by a grant from the European Commission to support projects on "Transatlantic methods for handling global challenges." It is based on independent research and does not represent the views of the European Commission or the Woodrow Wilson International Center for Scholars. For more information, go to: www.lse.ac.uk/nanoregulation.


'/>"/>
SOURCE Woodrow Wilson International Center for Scholars
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
2. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
3. Venter Institute Scientists Create First Synthetic Bacterial Genome
4. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
5. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
6. The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems
7. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
8. Synthetic Biology Importance in the 21st Century
9. A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):